NasdaqCM:DMRABiotechs
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed?
Damora Therapeutics, Inc. previously reported a second-quarter 2026 net loss of US$31.17 million and six-month net loss of US$58.96 million, closed a US$7.45 million ESOP-related shelf registration, and initiated the global Phase 1/1b CLARITY-101 trial of its investigational mutCALR-targeting antibody DMR-001 in essential thrombocythemia and myelofibrosis.
The launch of CLARITY-101 marks an important step toward a potential first mutCALR-targeted therapy for an underserved ET and MF patient...